# To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

> **NCT05405439** · PHASE1,PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 39 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** TQB3823 tablets
- **DRUG:** Abiraterone acetate tablets
- **DRUG:** prednisone acetate tablets

## Key facts

- **NCT ID:** NCT05405439
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-25
- **Primary completion:** 2023-07-19
- **Final completion:** 2023-07-19
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** The sponsor voluntarily terminated the study
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405439, "To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05405439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*